Huma Khusro, MD
Psychiatry · Gadsden, ALNPI 1104929587
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 343 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,375 and has fallen 63.9% since, to $496 in 2025.
Across 343 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$585
- Teva Pharmaceuticals USA, Inc.$562
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$510
- Bausch Health US, LLC$484
- Johnson & Johnson$444
- plus $2K from 13 others
What the payments were for
- Food & beverage$5,43698%
- Education$1352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 56 | $1,131 |
| Otsuka America Pharmaceutical, Inc. | 37 | $585 |
| Teva Pharmaceuticals USA, Inc. | 33 | $562 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $510 |
| Bausch Health US, LLC | 32 | $484 |
| Johnson & Johnson | 28 | $444 |
| AbbVie(2 entities) | 31 | $425 |
| Vanda Pharmaceuticals Inc. | 31 | $424 |
| Neurocrine Biosciences, Inc. | 19 | $362 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $201 |
| Indivior Inc. | 10 | $139 |
| E.r. Squibb & Sons, L.L.C. | 5 | $91 |
| Lundbeck LLC | 6 | $79 |
| Axsome Therapeutics, Inc. | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| Corium, LLC | 2 | $21 |
| Noven Therapeutics, LLC | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$5,572 in reported general payments places this provider in the 85th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 102 | $236,764 |
| Abilify MaintenaAripiprazole | 63 | $170,310 |
| AristadaAripiprazole Lauroxil | 52 | $135,722 |
| RexultiBrexpiprazole | 50 | $71,766 |
| VraylarCariprazine Hcl | 46 | $61,977 |
| TrintellixVortioxetine Hydrobromide | 30 | $22,502 |
| CaplytaLumateperone Tosylate | 12 | $19,411 |
| SaphrisAsenapine Maleate | 13 | $19,113 |
| Aripiprazole | 224 | $11,816 |
| Bupropion XlBupropion Hcl | 221 | $6,507 |
| Clonazepam | 370 | $5,535 |
| Quetiapine Fumarate | 345 | $5,041 |
| Duloxetine Hcl | 228 | $4,448 |
| Fluphenazine Hcl | 32 | $4,060 |
| Buspirone Hcl | 248 | $3,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $585 | $242,076113 claims |
| Johnson & JohnsonInvega Sustenna | $444 | $236,764102 claims |
| Alkermes, Inc.Aristada | $1,131 | $135,72252 claims |
| AbbVieVraylar, Saphris | $425 | $81,09059 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $201 | $22,50230 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $510 | $19,41112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Gadsden
- Benjamin CarrGadsden$18K
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Scariya KumaramangalamHuntsville$440K
- Mark HaygoodMobile$348K
- Lori DavisTuscaloosa$161K
- Bradley SadlerMobile$124K
- Brandi Rudolph BollingJasper$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.